Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MOXR0916 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MOXR0916: Dose Escalation Stage | EXPERIMENTAL | Participants in different cohorts (according to MOXR0916 dose received) will receive escalating doses of MOXR0916 to determine the MTD or maximum administered dose (MAD) for 21 to 42 days. |
| MOXR0916: Expansion Stage | EXPERIMENTAL | Participants in different cohorts (according to different cancer types, prior therapy and mandatory procedures on study) will receive MOXR0916 at the highest dose level that has already been deemed to be tolerable in the dose escalation stage until disease progression, loss of clinical benefit or unacceptable toxicity, whichever occurred first (approximately up to 3 years). |
| Name | Type | Description |
|---|---|---|
| MOXR0916 | DRUG | MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle. |
Inclusion Criteria: * Histologic documentation of locally advanced, recurrent or metastatic incurable solid malignancy that has progressed after all available standard therapy or for which standard therapy has proven to be ineffective or intolerable, or is considered inappropriate * Confirmed avail...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
MOXR0916 is an investigational humanized agonist anti-OX40 monoclonal antibody being developed by Roche Holding AG for the treatment of neoplasms, including locally advanced or metastatic solid tumors. It is designed to stimulate immune responses against cancer and has been studied in a Phase 1 clinical trial.
MOXR0916 is being studied for use in patients with neoplasms, specifically locally advanced or metastatic solid tumors. It is not yet approved for any indication and remains an investigational therapy in clinical development.
MOXR0916 targets OX40, a costimulatory receptor on T cells. As a humanized agonist anti-OX40 monoclonal antibody, it is designed to activate OX40 signaling to enhance T-cell-mediated antitumor immune responses.
MOXR0916 is being developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is responsible for the clinical development of this anti-OX40 antibody.
MOXR0916 is in Phase 1 clinical development. It has completed one Phase 1 trial and is not currently listed as active in further trials. It is investigational and has not been approved by the FDA for any indication.
MOXR0916 has been evaluated in a completed Phase 1 trial, NCT02219724, titled "A Study to Assess Safety and Pharmacokinetics of MOXR0916 in Participants With Locally Advanced or Metastatic Solid Tumors." The trial enrolled 174 participants across the United States, Australia, Belgium, Canada, South Korea, and Spain.